BGNE BeiGene, Ltd. gains 73% Jul 24, 2017

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, the Cayman Islands. http://www.priceseries.com/trade/BGNE-BeiGene-Ltd-stock-gains-73-percent-a-Trade-Record-by-priceSeries-2017061620170724.html